In spite of the well-established understanding of the phenotypic lesions occurring in the shift from native epithelia to invasive （adeno） carcinoma, the molecular b/ping of the precancerous changes in the gastrointe...In spite of the well-established understanding of the phenotypic lesions occurring in the shift from native epithelia to invasive （adeno） carcinoma, the molecular b/ping of the precancerous changes in the gastrointes- tinal tract remains unreliable. In recent years, no biomarkers have aroused as much interest as the miRNAs, a class of non-coding RNA molecules that function as endogenous silencers of numerous target genes. Aberrant miRNA expression is a hallmark of human disease, including cancer. Unlike most mRNAs, miRNAs are both long-living in vivo and very stable in vitro. Such charac- teristics allow their testing in paraffin-embedded tissue samples, which is essential in the biological profiling of small （phenotypically characterized） preneoplastic lesions of the gastrointestinal tract （as well as in other fields of human pathology）. The upcoming challenge lies in the reliable identification of disease-specific targets of dysregulated miRNAs, to enable miRNA testing in the clinical management of the secondary prevention of gastrointestinal cancer.展开更多
基金Supported by The AIRC grant Veneto Region 2009the "G.Berlucchi" and "G.B. Morgagni" Foundations
文摘In spite of the well-established understanding of the phenotypic lesions occurring in the shift from native epithelia to invasive （adeno） carcinoma, the molecular b/ping of the precancerous changes in the gastrointes- tinal tract remains unreliable. In recent years, no biomarkers have aroused as much interest as the miRNAs, a class of non-coding RNA molecules that function as endogenous silencers of numerous target genes. Aberrant miRNA expression is a hallmark of human disease, including cancer. Unlike most mRNAs, miRNAs are both long-living in vivo and very stable in vitro. Such charac- teristics allow their testing in paraffin-embedded tissue samples, which is essential in the biological profiling of small （phenotypically characterized） preneoplastic lesions of the gastrointestinal tract （as well as in other fields of human pathology）. The upcoming challenge lies in the reliable identification of disease-specific targets of dysregulated miRNAs, to enable miRNA testing in the clinical management of the secondary prevention of gastrointestinal cancer.
